Nurofenflash

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nurofenflash

Quick Facts

Property Description
Active ingredient Ibuprofen Lysinate (salt form)
Form Film-coated tablet (oral administration)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common purpose Analgesic and Antipyretic action
Distinctive feature Engineered for rapid absorption
Manufacturer Reckitt Benckiser (as trade name holder)

Nurofenflash: Identity, Composition, and Pharmacological Class

Nurofenflash is a commercially available medication that belongs to the group of synthetic propionic acid derivatives. Its active component is Ibuprofen, a widely studied chemical entity that is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The product is typically sold as an over-the-counter (OTC) medicine in many markets, focusing on general symptomatic relief. This medicine is distinguished by its use of Ibuprofen Lysinate, a highly water-soluble salt form of Ibuprofen, rather than the free acid.

The Formulation: Ibuprofen Lysinate and its Dosage Form

This medication is delivered via oral administration primarily as a film-coated tablet or capsule, with the physical form designed to enhance speed. The inclusion of the Lysinate salt is a key differentiating feature, as this formulation is manufactured by the brand holder, Reckitt Benckiser, to enhance solubility. This enhanced water solubility ensures that the active ingredient achieves a rapid dissolution rate compared to standard Ibuprofen preparations. This specific formulation is engineered to achieve effective blood concentrations faster than standard Ibuprofen formulations.

General Therapeutic Purpose of the Medicine

The general purpose of this medicine is to offer foundational symptomatic relief by modulating the body's inflammatory and thermal processes. As an NSAID, Nurofenflash provides core analgesic (pain-relieving) and antipyretic (fever-reducing) properties. For example, it is utilized for general discomfort associated with headaches and elevated body temperature. The drug is clinically recognized as a reliable intervention for managing acute, non-specific symptomatic discomfort.

What side effects are possible with Nurofenflash?

Possible Side Effects and Safety Information

The safety profile for Ibuprofen Lysinate (Nurofenflash) is officially classified by regulatory authorities based on system-organ classes and estimated frequency. Adverse reactions are grouped as Common, Uncommon, Rare, Very Rare, or Not Known.

Frequency Category Rate per Population
Common ge 1/100 to < 1/10
Uncommon ge 1/1,000 to < 1/100

The most frequently reported effects classified as Common involve the Gastrointestinal System, including pyrosis (heartburn), abdominal pain, nausea, vomiting, and diarrhea. Uncommon effects include gastrointestinal ulcers, which may involve bleeding and perforation, as well as hypersensitivity reactions like skin rashes and asthma.

Serious Adverse Reactions

The regulatory safety profile highlights several serious adverse reactions, which are typically classified as Very Rare. These include Gastrointestinal Bleeding and Perforation, which can be fatal. Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have also been documented. Cardiovascular risk, including myocardial infarction (heart attack) and stroke, is noted, particularly with the use of high doses (ge 2,400 mg/day), though this risk is not observed at the lower doses commonly used in over-the-counter preparations.

Population and Exposure Constraints

Safety considerations apply specifically to the elderly, who face an increased frequency and severity of adverse reactions, particularly serious gastrointestinal events. The medicine is contraindicated during the third trimester of pregnancy due to documented fetal risks. Furthermore, the risk of Severe Cutaneous Adverse Reactions (SCARs) is noted to be highest early in therapy, while concerns regarding hepatic damage and hematopoietic disorders are associated with long-term exposure.

Overdose and Emergency Response

Overdose of Ibuprofen, the active substance in Nurofenflash, is officially documented as presenting with symptoms primarily affecting the gastrointestinal and central nervous systems. Initial clinical manifestations typically include nausea, vomiting, and abdominal pain, along with documented CNS effects such as dizziness, headache, and tinnitus. More severe or massive overdose scenarios may lead to profound CNS depression, resulting in serious conditions like seizures, loss of consciousness leading to coma, or severe confusion.

Significant physiological complications documented in regulatory sources include cardiovascular issues like hypotension and bradycardia, severe metabolic disturbances such as metabolic acidosis, and potential for transient acute renal failure. Serious gastrointestinal outcomes, including potentially fatal bleeding, ulceration, or perforation, are also officially noted. For pediatric cases, ingestion of 400 milligrams per kilogram of body weight or more is cited as a threshold likely requiring hospitalization and specialized observation.

Immediate medical attention must be sought in any suspected case of overdose. Regulatory bodies mandate contacting a Poison Control Center or going to the nearest emergency department right away. Management is specified as being primarily supportive and symptomatic, focusing on treating the observed clinical signs and monitoring vital signs. Official information confirms that no specific antidote is available for Ibuprofen overdose.

Therapeutic Uses of Nurofenflash

Nurofenflash: Main Uses and Benefits

The medication is commonly used to help with short-term symptomatic relief across several domains of acute discomfort. As a non-steroidal anti-inflammatory drug (NSAID), its therapeutic applications are well-established. The compound is commonly used to manage mild to moderate pain, fever, and associated symptoms in conditions presenting with systemic or localized discomfort. The medication is relevant for easing symptoms related to inflammatory or irritative states.

This formulation is applicable within clinical settings that involve acute or disruptive symptom patterns, such as routine headache, the discomfort of dental pain, and the elevated body temperature accompanying flu-like symptoms. It also plays a role in managing menstrual pain (primary dysmenorrhea). The specialized Lysinate formulation may assist with absorption, supporting an intended faster onset of action, which supports general comfort and functional stability during episodes of illness or pain.

“The medication is commonly used to help with supportive relief during phases when symptoms become more noticeable, assisting with maintaining functional stability.”

This assistance is particularly relevant when symptoms create noticeable interference with daily stability.


Quick Fact: Relief for Acute Discomfort

Property Description
Primary Actions Analgesia and Antipyresis
Pain Intensity Mild to Moderate
Target Conditions Headache, Dental Pain, Dysmenorrhea, Flu-like Symptoms
Relevant Benefit Support for symptomatic relief with an intended faster onset

Regulatory References

  1. NCBI StatPearls Overview on Ibuprofen

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nurofenflash — official regulatory information

Populations for whom use is allowed: Generally, Adults and children over 12 years of age (or those weighing over 30 kg) are eligible. All use is recommended for the shortest duration and at the lowest effective dose.


Populations for whom use is Contraindicated (Must Not Use):

  • Hypersensitivity: Individuals with a known allergy to ibuprofen, its excipients, aspirin, or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), which includes those with a history of asthma, rhinitis, or urticaria following NSAID exposure.
  • Gastrointestinal Issues: Patients with an active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes) or a history of gastrointestinal bleeding/perforation related to prior NSAID therapy.
  • Severe Organ Failure: Patients with severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure.
  • Pregnancy: Use is strictly contraindicated during the last (third) trimester of pregnancy.

Use Requires Special Consideration:

  • Children: Not for use by children under 12 years of age.
  • Elderly: Increased risk of adverse reactions, particularly gastrointestinal, requiring the lowest dose for the shortest period.
  • Systemic Diseases: Caution is necessary in patients with Systemic Lupus Erythematosus (SLE) or other connective tissue diseases.
  • Cardiovascular Conditions: Caution is advised for those with a history of hypertension or heart failure (not severe), or risk factors for arterial thrombotic events.
  • Other Restrictions: Use should be avoided with other concurrent NSAIDs. Consultation is advised if the patient is breastfeeding, attempting to conceive, or has Varicella (Chicken Pox).

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Nurofenflash (Ibuprofen Lysinate) is defined by restrictions on co-administration to manage risks related to gastrointestinal complications and altered drug exposure.

Category Documented Interaction Partners
Contraindicated Combinations Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, and high-dose Aspirin (Acetylsalicylic Acid).
Metabolic Interference Inhibitors of the CYP2C9 enzyme (e.g., fluconazole, voriconazole) may reduce the metabolic clearance of Ibuprofen, leading to increased plasma exposure of Nurofenflash.
Pharmacodynamic Risk Anticoagulants (e.g., warfarin), anti-platelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), and Corticosteroids pose an increased risk of gastrointestinal bleeding when co-administered.
Clearance Interference Ibuprofen reduces the renal clearance of drugs such as Lithium and Methotrexate, which is documented to increase the plasma levels and potential toxicity of these co-medications.

Timing-Based Administration Rule

When taken with low-dose Aspirin (for its anti-platelet effect), specific timing separation is required. Ibuprofen administration must be separated by at least 8 hours before or 30 minutes after the immediate-release low-dose Aspirin to avoid interference with the anti-platelet activity.

Substance Interaction Notes

The concurrent use of Alcohol may enhance adverse effects, particularly those affecting the gastrointestinal tract. Certain herbal products, such as Ginkgo Biloba, are also noted to increase the risk of bleeding.

Mechanism of Action

Inhibition of Eicosanoid Biosynthesis

The active component of Nurofenflash functions as a non-selective, reversible competitive inhibitor of the Cyclooxygenase (COX) enzymes (both COX-1 and COX-2). This targeted molecular action immediately suppresses the Arachidonic Acid Cascade, thereby halting the synthesis of mediators responsible for heightened thermal and nociceptive signaling, particularly Prostaglandin E2 (PGE2), which initiates the downstream physiological effects.


Regulation of Central and Peripheral Signaling

The drug's mechanism leads to dual physiological modulation: the central suppression of PGE2 within the hypothalamus allows the body's thermoregulatory set-point to revert toward a physiological baseline, while peripheral suppression decreases the excitability of peripheral nociceptors. This combined action modulates both the body's thermoregulatory response and the intensity of nociceptive input at the receptor level.


Mechanistic Limitations

The mechanism is intrinsically limited to modulating physiological responses that are Prostaglandin-mediated. The mechanism cannot interfere with physiological responses arising from non-eicosanoid pathways, nor can it reverse the effects of inflammatory mediators that have already been produced and released before the drug was taken.

Dosage and Administration Information

Official Administration Guidelines

Administration of Nurofenflash (Ibuprofen Lysinate) must strictly follow the labeled instructions to ensure proper use and dosing. The lowest effective dose should be used for the shortest duration necessary.

Instruction Domain Official Guideline
Route of Administration Oral use (swallowed).
Standard Single Dose 400 mg (Ibuprofen equivalent).
Dosing Interval A minimum interval of at least 6 hours must be left between doses.
Maximum Daily Dose Do not exceed 1200 mg (three 400 mg doses) in any 24-hour period.

Procedural and Time Constraints

Method of Use: The film-coated tablet must be swallowed whole with a glass of water; it should not be chewed or crushed. It is recommended that individuals with a sensitive stomach take the medicine with or after food.

Duration of Use: This medication is approved for short-term use only. Adults should consult a doctor if symptoms worsen, if the product is required for more than 3 days (for fever/migraine) or 4-5 days (for pain), or if new symptoms occur. Adolescents (12 years and above) should seek professional advice if the medicine is needed for more than 3 days.

Population Rules: Nurofenflash is not intended for use in children under 12 years of age or adolescents weighing less than 40 kg. No special dose adjustment is required for older adults or in cases of mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nurofenflash

The research evidence for Nurofenflash focuses on the clinical evaluation of its active component, Ibuprofen Lysinate. The following overview describes what types of studies have been conducted for its main uses, the outcomes research examined, and what aspects of the evidence remain uncertain, strictly based on authoritative sources.


Evidence for use in Acute Postoperative Dental Pain

Research exploring this specific medicine was often conducted in contexts of acute pain following surgical procedures, primarily involving short-term, randomized, double-blind trials, along with subsequent systematic reviews. These studies were used in research exploring how symptoms change over time in adult populations who underwent a standardized procedure. Researchers monitored patient-reported outcomes describing perceived discomfort and measures related to the time taken to observe changes in pain perception.

Findings describe patterns observed in the studies related to pain intensity measurement metrics when comparing Ibuprofen Lysinate against a placebo. In comparative studies with standard Ibuprofen acid, findings indicated that the overall measures used in pain studies were often similar when assessed over the full study period. However, the results apply only to the populations studied and follow-up durations were limited.


Evidence for use in Mild to Moderate Acute Pain

The evidence for the general management of acute discomfort relies on broader analyses, including systematic reviews and pharmacokinetic studies. These studies explored key metrics like peak blood concentration (Cmax) and the time to reach peak concentration (tmax), as this formulation was studied for accelerated absorption.

Pharmacokinetic research describes that the Lysinate formulation achieved Cmax at a shorter time interval compared to the standard formulation under fasting conditions. The overall measure of pain intensity measurement has been observed in some studies to be comparable between the Lysinate formulation and standard Ibuprofen.

Research has explored the clinical relevance of the accelerated absorption profile across different types of acute pain, and data remain mixed across various clinical pain models. Evidence suggests that food intake can appear to affect the rapid absorption benefit.


What is Still Uncertain About Nurofenflash Research

Evidence highlights what is known—and what is still uncertain—about this medication. A key research limitation is the ongoing discussion regarding the clinical relevance of the Lysinate salt's faster absorption profile compared to the well-established standard Ibuprofen. While pharmacokinetic research describes faster attainment of peak concentration, the corresponding comparison in the time to observe changes in pain perception has been mixed across different trials. Additionally, long-term effects are not fully established, and comparative evidence is lacking for certain specialized populations, such as older adults.

Frequently Asked Questions (FAQ)

Common questions about Nurofenflash (FAQ)


Q: Is Nurofenflash the same as regular Nurofen?

Nurofenflash contains Ibuprofen Lysinate, a specific salt formulation of ibuprofen. According to official product information, this formulation is studied for its potential to enhance the speed of absorption compared to standard ibuprofen preparations. Standard Nurofen may use a different formulation.

Q: Why is the word 'flash' in the name Nurofenflash?

The name Nurofenflash is consistent with the formulation's pharmacokinetic profile, which emphasizes rapid absorption. Regulatory data confirms that the Ibuprofen Lysinate salt is designed to reach its maximum concentration in the blood faster than the standard ibuprofen acid formulation.

Q: How does Nurofenflash differ from generic ibuprofen?

Nurofenflash uses Ibuprofen Lysinate, a water-soluble salt form. This specific formulation is distinguished from standard ibuprofen acid, which is the active ingredient in most generics, by its enhanced solubility. Official documentation indicates that this change is intended to support faster absorption from the gastrointestinal tract.

Q: Is Nurofenflash suitable for period pain?

Yes, official documentation indicates that Nurofenflash is generally indicated for the symptomatic treatment of pain associated with primary dysmenorrhoea, which is the medical term for common period pain.

Q: How quickly do people usually feel the effects of Nurofenflash?

Pharmacokinetic research indicates that the Lysinate formulation achieves its maximum blood concentration faster than standard ibuprofen. While individual experience varies, the accelerated absorption profile is studied in relation to changes in the perception of pain.

Q: What is the expected duration of effect after taking one dose of Nurofenflash?

The official administration guidelines state that if necessary, a subsequent dose may be taken after a minimum interval of six hours. Clinical evidence has described the pain-relieving effects of a single dose in studies as lasting for up to eight hours, aligning with the official dosing interval.

Q: What should I do if I forget to take a dose of Nurofenflash?

Regulatory documents do not contain specific instructions for a forgotten dose. The primary guidance emphasizes that the maximal daily dose must not be exceeded and that a minimum of six hours passes between doses. The medicine may be resumed when needed, ensuring the minimal time interval is maintained.

Q: Does Nurofenflash interact with alcohol?

Regulatory warnings indicate that the concurrent use of alcohol may enhance the side effects of Ibuprofen Lysine. This enhancement is noted particularly for adverse effects affecting the central nervous system and the gastrointestinal tract.

Q: Can people with asthma use Nurofenflash?

Official contraindications state that use is not allowed for individuals with a history of hypersensitivity reactions to aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs). This includes those who have previously experienced asthma, rhinitis, or hives (urticaria) after taking an NSAID.

Q: What does the research say about the formulation of Nurofenflash?

Research focuses primarily on the Ibuprofen Lysinate formulation's accelerated absorption profile. Studies have shown that this formulation achieves a shorter time to reach peak concentration in the blood compared to standard ibuprofen. However, the clinical relevance of this faster absorption in terms of overall pain relief remains a subject of ongoing discussion in the evidence base.

Q: Why do official documents mention taking Nurofenflash with a glass of water?

The official instructions specify taking the tablet with a large glass of water. This ensures the correct oral administration and assists the specific film-coated tablet in its proper and rapid dissolution, supporting the intended fast-acting characteristic of the medicine.

Q: Can Nurofenflash be taken on an empty stomach?

Official information indicates that taking the medicine on an empty stomach may lead to more rapid absorption. However, the guidance generally recommends that individuals who have a sensitive stomach take the medicine with or immediately after food.

Q: Is it okay if I break the tablet in half?

Official instructions state that the film-coated tablet must be swallowed whole with a glass of water. It should not be chewed, crushed, or broken in half, as this may interfere with the way the formulation is designed to work.

Q: What are the signs of an allergic reaction to Nurofenflash?

Official drug labels state that severe allergic reactions can occur. Signs can include hives, swelling of the face, wheezing or difficulty breathing (asthma), skin reddening, rash, and blistering. If any of these serious reactions are observed, it is noted that immediate medical attention is necessary.

Q: What is the scientific basis for the 'rapid' claim in Nurofenflash?

The scientific basis is rooted in the use of the highly water-soluble Lysinate salt form of ibuprofen. This formulation is associated with enhanced solubility, allowing the active ingredient to achieve peak blood concentration at a shorter time interval compared to the standard ibuprofen acid formulation, as described in scientific evidence.

Q: Can Nurofenflash be used by breastfeeding mothers?

Official eligibility documents advise that consultation with a healthcare professional is required if a patient is breastfeeding. Evidence from authoritative sources indicates that ibuprofen is transferred into breast milk in very low concentrations, but individual medical advice is always necessary in this context.

Q: Is Nurofenflash generally considered suitable for older adults?

Older adults have an officially noted increased risk of adverse reactions to NSAIDs, particularly serious gastrointestinal events. Regulatory guidance states that the lowest effective dose should be used for the shortest possible duration, and long-term use is generally not advised for this population.

Q: Does taking Nurofenflash affect fertility in men or women?

Official guidance advises consultation if the patient is attempting to conceive. Studies suggest that taking ibuprofen in large doses or for a long time can potentially affect ovulation, which may make it more difficult to become pregnant. The official guidance advises consultation, and studies suggest that this effect is considered reversible when the drug is stopped.

Q: Can I take Nurofenflash if I'm taking a low-dose aspirin regimen?

Specific timing separation is required when co-administering with low-dose aspirin (for anti-platelet effect). Regulatory documents specify that Ibuprofen must be administered at least 8 hours before or 30 minutes after taking the immediate-release low-dose aspirin to avoid interference with its anti-platelet activity.

Q: Can Nurofenflash be used for muscle aches and strains?

The general purpose of the medicine is to provide relief through its official analgesic (pain-relieving) properties. The drug is indicated for general symptomatic discomfort, which can include muscle aches and pains.

Q: Why is Nurofenflash sometimes referred to as 'ibuprofen lysine' as well?

Ibuprofen Lysinate is the official name for the specific chemical salt used as the active component in the medicine. While Nurofenflash is the registered trade name, the product is sometimes referred to by its active chemical identity.

Q: Can people with liver impairment use Nurofenflash?

The medicine is contraindicated in patients who have severe hepatic (liver) failure. However, official information states that no special dose adjustment is required for individuals with mild to moderate hepatic impairment, though the use of caution is still advised.

Q: How do the active ingredients in Nurofenflash get absorbed?

After oral administration, the Ibuprofen Lysinate salt rapidly dissolves and dissociates into Ibuprofen acid and Lysine. The Ibuprofen acid is then well absorbed through the lining of the gastrointestinal tract. The specific formulation is engineered to support an acceleration of this overall process.

Q: Does Nurofenflash have a coating, and what is its purpose?

The product is manufactured as a film-coated tablet. The coating serves a protective function, ensuring the stability and integrity of the tablet. It also facilitates that the tablet can be swallowed whole, as required by administration instructions.

Q: Is Nurofenflash considered a long-term or short-term treatment?

Official regulatory documents define this medication for short-term use only. Prolonged or continuous therapy with this class of medicine is noted as requiring regular review and assessment by a healthcare professional.

Q: Do the side effects of Nurofenflash get worse with prolonged use?

The risk of some serious adverse reactions is associated with long-term exposure to NSAIDs. Regulatory warnings highlight that risks related to gastrointestinal bleeding or ulceration, as well as concerns regarding liver and blood cell disorders, are noted in the context of prolonged use.

How should Nurofenflash be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define the mandatory handling and storage conditions for Nurofenflash film-coated tablets.

Scope Area Regulatory Statement
Storage Temperature This medicinal product does not require any special storage conditions.
Packaging Keep in the original container (blister and carton) to maintain product integrity and protect it from environmental factors.
Child Safety Keep out of the sight and reach of children to prevent accidental ingestion.
Disposal No special requirements are listed for the disposal of the product.

Official Storage and Disposal Profile

The regulatory profile for Nurofenflash requires ambient storage since no special temperature or environment controls are necessary. The tablets must be stored in the original packaging to protect the product. For disposal of any unused or expired tablets, official guidelines advise against discarding them in household waste or flushing them; they should be returned to a pharmacist or local collection service.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nurofenflash found in:

A-Z Index: